NKTR Stock Summary

• Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; just 8.29% of US stocks have a lower such ratio.
• With a price/sales ratio of 34.27, Nektar Therapeutics has a higher such ratio than 95.98% of stocks in our set.
• Revenue growth over the past 12 months for Nektar Therapeutics comes in at -90.35%, a number that bests only 0.86% of the US stocks we're tracking.
• Stocks that are quantitatively similar to NKTR, based on their financial statements, market capitalization, and price volatility, are NVAX, ARDS, UMRX, ANAB, and UTHR.
• NKTR's SEC filings can be seen here. And to visit Nektar Therapeutics's official web site, go to www.nektar.com.